Abstract:Abstract: The tumor suppressor protein p53, a transcription factor playing a key role in cancer prevention, interacts with DNA as its primary means of determining cell fate in the event of DNA damage. When it becomes mutated, it opens damaged cells to the possibility of reproducing unchecked, which can lead to formation of cancerous tumors. Despite its critical role, therapies at the molecular level to restore p53 native function remain elusive, due to its complex nature. Nevertheless, considerable information has been amassed, and new means of investigating the problem have become available. Objectives: We consider structural, biophysical, and bioinformatic insights and their implications for the role of direct and indirect readout and how they contribute to binding site recognition, particularly those of low consensus. We then pivot to consider advances in computational approaches to drug discovery. Materials and methods: We have conducted a review of recent literature pertinent to the p53 protein. Results: Considerable literature corroborates the idea that p53 is a complex allosteric protein that discriminates its binding sites not only via consensus sequence through direct H-bond contacts, but also a complex combination of factors involving the flexibility of the binding site. New computational methods have emerged capable of capturing such information, which can then be utilized as input to machine learning algorithms towards the goal of more intelligent and efficient de novo allosteric drug design. Conclusions: Recent improvements in machine learning coupled with graph theory and sector analysis hold promise for advances to more intelligently design allosteric effectors that may be able to restore native p53-DNA binding activity to mutant proteins. Clinical relevance: The ideas brought to light by this review constitute a significant advance that can be applied to ongoing biophysical studies of drugs for p53, paving the way for the continued development of new methodologies for allosteric drugs. Our discoveries hold promise to provide molecular therapeutics which restore p53 native activity, thereby offering new insights for cancer therapies. Graphical abstract: Structural representation of the p53 DBD (PDBID 1TUP). DNA consensus sequence is shown in gray, and the protein is shown in blue. Red beads indicate hotspot residue mutations, green beads represent DNA interacting residues, and yellow beads represent both.

In-silico Evaluation of Structurally Homologous Drosophila p53 with Human p53 to Identify Functional Differences for Future Therapeutic Research

Navigating the complexity of p53-DNA binding: implications for cancer therapy

Functional Diversity of P53 in Human and Wild Animals

Small Molecule Inhibitors of the P53-Mdm2

In Silico Screening, Molecular Dynamics Simulation and Binding Free Energy Identify Single-Point Mutations That Destabilize p53 and Reduce Binding to DNA

Integrating mutation data and structural analysis of the TP53 tumor‐suppressor protein

Molecular dynamics-based computational investigations on the influence of tumor suppressor p53 binding protein against other proteins/peptides

Structural modulation of p53TAD1-TAZ2 complex upon mutations and post-translational modification

Identification of mutant p53-specific proteins interaction network using TurboID-based proximity labeling

Synthesis, characterization, and anti-cancer potential of novel p53-mediated Mdm2 and Pirh2 modulators: an integrated In silico and In vitro approach

The initial evaluation of non-peptidic small-molecule HDM2 inhibitors based on p53-HDM2 complex structure.

Full-atomistic Molecular Dynamics Analysis of p53 Active Tetramer

The effects of p53 gene inactivation on mutant proteome expression in a human melanoma cell model

A yeast two-hybrid system for the screening and characterization of small-molecule inhibitors of protein-protein interactions identifies a novel putative Mdm2-binding site in p53

Integrated virtual screening and molecular dynamics simulation revealed promising drug candidates of p53-MDM2 interaction

Working title: Molecular involvement of p53‐MDM2 interactome in gastrointestinal cancers

Design of peptide-based foldamers for inhibiting the Hdm2-p53 interaction using backbone modification: a molecular dynamics study

Small-molecule inhibitors of the p53-HDM2 interaction for the treatment of cancer

Insight on Heterocycles as p53‐MDM2 Protein‐Protein Interaction Inhibitors: Molecular Mechanism for p53 Activation

Unraveling The Allosteric Mechanism Of Four Cancer-Related Mutations In The Disruption Of P53-Dna Interaction

Predicting Transcriptional Activity of Multiple Site P53 Mutants Based on Hybrid Properties.